SERENTIL
LOE ApproachingNDAORALCONCENTRATE
Approved
Jan 1972
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 22h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SERENTIL is an oral concentrate small-molecule antipsychotic approved in 1972 for psychiatric indications. The generic name and specific mechanism of action are not currently available in this dataset. This is a legacy NDA product with a well-established safety and efficacy profile in schizophrenia and related psychotic disorders.
LOE Approaching
Moderate competitive pressure (30%) signals a mature market with generic alternatives; expect a smaller, focused team managing market share defense and cost optimization.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings suggest this is a maintenance-stage product with limited hiring activity and career advancement opportunities within the SERENTIL team. Professionals seeking roles on this brand should expect focus on market defense, cost management, and payer negotiations rather than growth or innovation projects.
Brand ManagerField Sales Representative
Worked on SERENTIL at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.